Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr1231 Inhibitors

Olr1231 inhibitors are a distinct class of chemical compounds that are specifically designed to interact with and inhibit the function of the Olr1231 receptor, a member of the olfactory receptor family within the G protein-coupled receptor (GPCR) superfamily. Olr1231 receptors, like other olfactory receptors, are involved in the detection of odorant molecules and play a key role in the olfactory system's ability to translate chemical signals into neural signals that are interpreted as smells. These inhibitors work by binding to the receptor at its active site or other regulatory regions, thereby blocking the receptor's ability to interact with its natural ligands or prevent the conformational changes necessary for signal transduction. The development of Olr1231 inhibitors often involves detailed studies of the receptor's structure, using techniques such as X-ray crystallography, molecular modeling, and cryo-electron microscopy. These structural insights are essential for designing inhibitors that are both highly specific and effective in targeting the Olr1231 receptor without affecting other similar receptors.

Chemically, Olr1231 inhibitors are characterized by a wide range of molecular structures and properties, reflecting the diverse approaches used in their synthesis. These inhibitors may be small, lipophilic molecules that can easily penetrate cellular membranes to reach their target receptor. Alternatively, they may be larger, more complex molecules that require specific modifications or delivery systems to enhance their binding affinity and specificity. The synthetic pathways to create Olr1231 inhibitors often involve multiple steps of organic synthesis, including the formation of key functional groups that are critical for binding to the receptor. After synthesis, these compounds undergo extensive characterization using techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and high-performance liquid chromatography (HPLC) to confirm their structural integrity, purity, and inhibitory potency. The study of Olr1231 inhibitors contributes to a deeper understanding of the molecular mechanisms underlying olfaction, particularly how specific olfactory receptors function and how their activity can be modulated by small molecules. Additionally, this research enhances the broader field of GPCR modulation, offering valuable insights into how these receptors can be selectively targeted and regulated, which is crucial for advancing our knowledge of sensory perception and the complex biochemical processes involved in the sense of smell.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Multi-kinase inhibitor, potentially targets angiogenesis and tumor cell growth.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

Targets EGFR, VEGFR, and RET kinases, possibly affecting cancer cell signaling.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK1/2 inhibitor, may affect cytokine signaling involved in myeloproliferative disorders.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

BCR-ABL inhibitor, potentially useful in chronic myeloid leukemia.

AP 24534

943319-70-8sc-362710
sc-362710A
10 mg
50 mg
$175.00
$983.00
2
(1)

Multi-target kinase inhibitor, might affect BCR-ABL, including T315I mutation.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor, potentially delays cell cycle progression in breast cancer.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

SRC and BCR-ABL inhibitor, could affect cell growth in certain leukemias.

CH5424802

1256580-46-7sc-364461
sc-364461A
5 mg
50 mg
$191.00
$902.00
(0)

ALK inhibitor, potentially effective in ALK-positive non-small cell lung cancer.

Cobimetinib

934660-93-2sc-507421
5 mg
$270.00
(0)

MEK inhibitor, might affect cell signaling in melanoma with BRAF V600 mutations.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Multi-kinase inhibitor, could inhibit angiogenesis and tumor cell growth.